Quote | Immunome Inc. (NASDAQ:IMNM)
Last: | $13.73 |
---|---|
Change Percent: | -0.14% |
Open: | $14.28 |
Close: | $13.73 |
High: | $14.39 |
Low: | $13.7 |
Volume: | 967,406 |
Last Trade Date Time: | 04/26/2024 03:00:00 am |
News | Immunome Inc. (NASDAQ:IMNM)
Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced the appointment of Sandra M. Swain, M.D., to its Board of Directors. Dr. Swain has over 30 years of oncology clinical research experience and ha...
2024-04-22 10:18:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
Message Board Posts | Immunome Inc. (NASDAQ:IMNM)
Subject | By | Source | When |
---|---|---|---|
Ha, sold in fall of 21 for $25. | wiwineguy | investorshub | 06/29/2023 1:42:46 PM |
$IMNM: Now 10.40 !!!!!!!!!!! | makinezmoney | investorshub | 06/29/2023 1:13:11 PM |
$IMNM: Boooommmmmmmmmmmmmmm.......now $8.50 | makinezmoney | investorshub | 06/29/2023 1:07:40 PM |
Immunome and Morphimmune Announce Definitive Merger Agreement and | Awl416 | investorshub | 06/29/2023 1:03:28 PM |
Good read | Major_Bankz | investorshub | 06/27/2023 4:07:56 PM |
News, Short Squeeze, Breakout and More Instantly...
Immunome Inc. Company Name:
IMNM Stock Symbol:
NASDAQ Market:
Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced the appointment of Sandra M. Swain, M.D., to its Board of Directors. Dr. Swain has over 30 years of oncology clinical research experience and ha...
2024-04-22 10:18:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced that it will present preclinical data for IM-3050, the company’s lead lutetium-177 radioligand therapy (RLT) targeting fibroblast activat...